Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-03-06Clinical Trial Update: Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS [NA]
A clinical study is evaluating an innovative CAR-T cell therapy that targets IL-1RAP in patients with high-risk myelodysplastic syndromes; t…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome [Phase 2]
Phase 2 trial evaluating nivolumab and/or ipilimumab with or without azacitidine for myelodysplastic syndromes; currently active but not rec…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory [Phase 1]
A Phase 1 clinical trial evaluating pembrolizumab plus decitabine, with or without venetoclax, for patients with acute myeloid leukemia or m…
-
CLINICAL_TRIALS research · 2026-03-05Clinical Trial Update: Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA [Phase 1, Phase 2]
A Phase 1/2 clinical trial evaluating the combination of luspatercept in lower-risk myelodysplastic syndromes patients who have failed or ar…
-
CLINICAL_TRIALS trial_result · 2026-03-04Clinical Trial Update: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies [Phase 2]
Phase 2 clinical trial update evaluating TCRαβ-depleted progenitor cell graft with added memory T-cell donor lymphocyte infusion and selecti…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. [Phase 2]
Phase 2 study evaluating olutasidenib in IDH1-mutated clonal cytopenia of undetermined significance and lower-risk myelodysplastic syndromes…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies [Phase 1]
A Phase 1 clinical trial update for a study of novel anti-leukemia agents used in Flu/Mel reduced-intensity conditioning transplant for myel…
-
CLINICAL_TRIALS research · 2026-03-04Clinical Trial Update: IFN-α in Relapse Prevention. [Phase 2]
Phase 2 clinical trial update evaluating interferon alpha for relapse prevention in acute myeloid leukemia and myelodysplastic syndromes; no…
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome [Phase 1]
Phase 1 study of pevonedistat in combination with belinostat for relapsed or refractory acute myeloid leukemia or myelodysplastic syndromes …
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Chemogenomic Profiling in Hematological Malignancies (HEM-Profiling 2021) [NA]
A hematology-focused clinical trial update for HEM-Profiling 2021, currently recruiting to explore chemogenomic profiling across multiple le…
-
CLINICAL_TRIALS trial_result · 2026-03-03Clinical Trial Update: CD34+ Enriched Transplants to Treat Myelodysplastic Syndrome [Phase 2]
This Phase 2 trial of CD34+ enriched transplants to treat myelodysplastic syndromes is currently suspended.
-
CLINICAL_TRIALS research · 2026-03-03Clinical Trial Update: Feasibility of a Multi-omics Platform for Hematological Malignancies [NA]
This clinical trial update assesses the feasibility of a multi-omics platform for hematological malignancies and is currently recruiting. It…
-
CLINICAL_TRIALS research · 2026-03-02Clinical Trial Update: AML/MDS Drug Sensitization by in Vivo Chemotherapy Administration
A clinical trial update from Washington University School of Medicine on in vivo chemotherapy–mediated drug sensitization for acute myeloid …
-
CLINICAL_TRIALS trial_result · 2026-02-27Clinical Trial Update: MBG453 in Lower Risk MDS [Phase 2]
A Phase 2 trial of MBG453 for lower-risk myelodysplastic syndromes has been terminated, with results posted.
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood [Phase 2]
Phase 2 clinical trial evaluating co-transplant of an unmodified haplo-identical graft with cord blood; the study targets acute graft-versus…
-
CLINICAL_TRIALS research · 2026-02-27Clinical Trial Update: A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome [Phase 2]
A Phase 2 clinical trial is evaluating the efficacy and safety of AND017 in patients with Myelodysplastic Syndromes and is currently recruit…
-
CLINICAL_TRIALS research · 2026-02-25Clinical Trial Update: A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS) [Phase 2, Phase 3]
This ClinicalTrials.gov entry notes a Phase 2/3 study comparing oral azacitidine plus best supportive care versus placebo plus best supporti…
-
CLINICAL_TRIALS withdrawal · 2026-02-24Clinical Trial Update: Cryopreserved MMUD BM With PTCy for Hematologic Malignancies [Phase 1]
Phase 1 trial of cryopreserved MMUD bone marrow with post-transplant cyclophosphamide for hematologic malignancies has been withdrawn.
-
CLINICAL_TRIALS research · 2026-02-24Clinical Trial Update: Predictive Value of Myelodysplastic Syndrome Stem Cells Determined by Multiparameter Flow Cytometry
A clinical trial at Peking University People's Hospital is evaluating whether multiparameter flow cytometry of myelodysplastic syndrome stem…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies [Phase 1]
This clinical trial update describes a Phase 1 study of Orca-Q for patients with hematologic malignancies undergoing allogeneic stem cell tr…
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT [NA]
Clinical trial update indicates ongoing recruitment for a study evaluating CD45RA-depleted peripheral stem cell addback to prevent viral or …
-
CLINICAL_TRIALS research · 2026-02-20Clinical Trial Update: Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care [NA]
This clinical trial update describes a University of Miami-sponsored study evaluating how Leukemia & Lymphoma Society services affect patien…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS [Phase 2, Phase 3]
A phase 2/3 clinical trial is investigating venetoclax in combination with a fractionated busulfan conditioning regimen for high-risk acute …
-
CLINICAL_TRIALS research · 2026-02-18Clinical Trial Update: ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome [Phase 1, Phase 2]
Ongoing Phase 1/2 clinical trial evaluating the combination of ASTX727, venetoclax, and gilteritinib for newly diagnosed, relapsed or refrac…
-
CLINICAL_TRIALS trial_result · 2026-02-17Clinical Trial Update: A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States
The completed study, sponsored by Bristol-Myers Squibb, evaluates luspatercept treatment patterns and outcomes in ESA-naïve patients with lo…